UNSPSC 51372039: Morphine tartrate

This classification denotes an opioid receptor agonist with the molecular formula 2C17H19NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3NSU23LHD. European Medicines Agency schedules morphine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14598MIG. The term morphine tartrate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule morphine tartrate under HS 29391100 and SITC 54141.

As of Q4 2014, MORPHINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51372039 Morphine tartrate, a Commodity code, encompasses the procurement of opioid pharmaceutical products for state and local health systems, emergency response programs, and pharmacy benefit initiatives. The recent state and local opportunities tagged under this code reveal that purchasing bodies are procuring naloxone (an opioid antagonist), generic multi-source pharmaceuticals including controlled substances, and associated delivery systems through competitive bidding and cooperative purchasing frameworks. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Purchases are driven by community health initiatives, pharmacy benefit management modernization, and opioid response programming. Vendors must typically demonstrate FDA compliance, current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and established relationships with authorized pharmaceutical wholesalers; many solicitations require E-Verify compliance and standard insurance coverages including commercial general liability and professional liability.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, reflecting state interest in alternative pharmacy benefit structures. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026. Vendors must work through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co. as authorized wholesalers and agree to 3 percent administrative fees. No specific set-aside designations are evident across the recent opportunities.